Go Pro
→ Jon Najarian's #1 Energy Trade for 2026 (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$9.76
+3.4%		$8.93
$3.92
▼
$19.15
$97.97M0.1672,132 shs19,611 shs
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
$18.99
$18.99
$7.01
▼
$19.30
$655.69MN/A205,753 shsN/A
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
+2.05%-7.72%+16.69%-2.38%-20.94%
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$9.76
+3.4%		$8.93
$3.92
▼
$19.15
$97.97M0.1672,132 shs19,611 shs
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
$18.99
$18.99
$7.01
▼
$19.30
$655.69MN/A205,753 shsN/A
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
+2.05%-7.72%+16.69%-2.38%-20.94%
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
2.50
Moderate Buy$9.50-2.66% Downside
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ATRA and OSIR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/24/2026
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/18/2026
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/31/2026
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/15/2026
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 9/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$6.19M15.82$5.14 per share1.90($5.34) per share-1.83
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
$32.69M-$1.18N/A7.07N/A-269.42%-79.12%-73.01%10/29/2026 (Estimated)
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest ATRA and OSIR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
-$0.3150-$0.32-$0.0050-$0.32$0.55 million$0.63 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
N/AN/AN/AN/AN/A
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
N/A
1.98
1.98
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
70.90%
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
0.28%

Insider Ownership

CompanyInsider Ownership
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
41.20%
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
43.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Atara Biotherapeutics, Inc. stock logo
ATRA
Atara Biotherapeutics
33010.04 million5.90 millionNo Data
Osiris Therapeutics, Inc. stock logo
OSIR
Osiris Therapeutics
34234.53 millionN/ANot Optionable

Recent News About These Companies

Osiris Chairman responds to column
December 24, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/osiris-chairman-responds-to-column
Stem Cell Market to Reach US$ 50.7 Billion by 2032, Growing at 10.7% CAGR Fueled by Advancements in Regenerative Medicine and Cell-Based Therapies
July 16, 2025  |  taiwannews.com.twT
Ryoncil, the first FDA-approved mesenchymal stromal cell therapy
March 3, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/ryoncil-first-fda-approved-mesenchymal-155711761.html?fr=sycsrp_catchall
Global Medical Disposables Market to be worth USD 326.4 Billion by 2033, Reveals Future Market Insights
December 18, 2024  |  fmiblog.comF
Human Osteoblasts Market Projected to Reach USD 85.3 Million by 2034 at a 6.4% of CAGR
October 31, 2024  |  fmiblog.comF
Global Medical Disposables Market to Reach USD 326…
October 24, 2024  |  pharmiweb.comP
Global Regenerative Medicine Market to Reach $472.95 Billion by 2032 | 25.86% CAGR
October 3, 2024  |  taiwannews.com.twT
Wound Care Biologics Market Future Looks Bright for Market Size with Soaring Projections
September 23, 2024  |  taiwannews.com.twT
Smith & Nephew buys Osiris in regenerative medicine push
July 25, 2024  |  pharmaphorum.comP
Type 1 Diabetes Drugs Market Revenue, Price, Growth Rate, Forecast To 2032
July 19, 2024  |  taiwannews.com.twT
Active Wound Care Market to Grow at 5.5% CAGR Through 2032 Amid Rising Chronic Wound Cases
May 29, 2024  |  pharmiweb.comP
Global Topical Wound Agents Market Size To Exceed USD 3.7 Billion By 2033 | CAGR Of 6.89%
May 25, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/global-topical-wound-agents-market-200000042.html
Cell and Gene Therapy Market Power of Anticipation Preparing for the Future of Market Size
May 2, 2024  |  taiwannews.com.twT
Tissue Engineering and Regeneration Market [2028]: Navigating Opportunities and Challenges
April 24, 2024  |  informazione.itI
Knee Cartilage Repair Market Growth Analysis, Size, Prominent Players, Overview, and Forecast 2024 to 2032
April 19, 2024  |  taiwannews.com.twT
Knee Cartilage Repair Market Size, Share, Growth Statistics, Latest Trends, and Forecast 2024 to 2032
April 12, 2024  |  taiwannews.com.twT
Global Anti-Biofilm Wound Dressing Market Projected to Witness Significant Growth US$ 1939.45 million by 2033
April 8, 2024  |  fmiblog.comF
Kanak Kanti
March 19, 2024  |  fool.comhttps://www.fool.com/author/5219/
Arnold Caplan, biologist who studied cells, dies at 82
February 11, 2024  |  cleveland.comC
Tissue Engineering Market Set to Soar Past USD 32.45 Billion by 2030
February 2, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/tissue-engineering-market-set-soar-153000091.html

Media Sentiment Over Time

Atara Biotherapeutics stock logo

Atara Biotherapeutics NASDAQ:ATRA

$9.76 +0.32 (+3.39%)
As of 11:38 AM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Osiris Therapeutics stock logo

Osiris Therapeutics OTCMKTS:OSIR

$18.99 0.00 (0.00%)
As of 04/17/2019

Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas